Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Parallel-group, Double-blind, Single-center Phase III Study to Assess the Immunogenicity and Safety of the 2011/2012-season Influenza Vaccine Formulated With HA Antigen From Two Suppliers, in Elderly and Young Adult Subjects Using the Current EMA Regulations as Guideline

NCT01412281 is registered in ClinicalTrials.gov with Crucell Holland BV as lead sponsor.

NCT NCT01412281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01412281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Parallel-group, Double-blind, Single-center Phase III Study to Assess the Immunogenicity and Safety of the 2011/2012-season Influenza Vaccine Formulated With HA Antigen From Two Suppliers, in Elderly and Young Adult Subjects Using the Current EMA Regulations as Guideline
Lead sponsor
Crucell Holland BV
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2011
Completion date
December 31, 2011
Enrollment
440 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza